Thomas Castellano
Director of Finance/CFO en ABZENA PLC .
Fortuna: 708 165 $ al 31/03/2024
Perfil
En la actualidad, Thomas P. Castellano es Vicepresidente Global de Finanzas Operativas en Catalent, Inc. También forma parte del consejo de administración de Catalent France Beinheim SA. El Sr. Castellano se licenció y obtuvo un MBA en la Universidad de Seton Hall.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
CATALENT INC
0.01% | 04/12/2023 | 12 545 ( 0.01% ) | 708 165 $ | 31/03/2024 |
Cargos activos de Thomas Castellano
Empresas | Cargo | Inicio |
---|---|---|
ABZENA PLC | Director of Finance/CFO | 05/06/2023 |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Director/Board Member | - |
Catalent Belgium Holding SA | Director/Board Member | 05/08/2021 |
Antiguos cargos conocidos de Thomas Castellano.
Empresas | Cargo | Fin |
---|---|---|
CATALENT, INC. | Director of Finance/CFO | 13/04/2023 |
Formación de Thomas Castellano.
Seton Hall University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CATALENT, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Catalent Belgium Holding SA | |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Health Technology |
Abzena Ltd.
Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Thomas Castellano